Cancer Immunology – News and Features

Researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR T-cell therapy. Over time, the engineered immune cells age and lose their ability to fight cancer.

Researchers have identified a signaling loop involved in the growth and persistence of leukemia cells, and developed a novel immunotherapy that can disrupt that loop to boost immune function and improve survival.

Discover what glycan analysis can reveal about protein behavior and how it can be used to boost biologic performance and ensure therapeutic quality in biopharmaceutical drug development.

Researchers developed a nasal antibody that blocks mugwort pollen, a major hay fever trigger in Europe and Central Asia. Delivered intranasally, it reduced allergic symptoms and inflammation in mice without systemic side effects.

Results of a phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine is safe, feasible and improves the vaccine-specific immune response generated.

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive.

A new study, for the first time, shows how exercise improves cancer outcomes and enhances response to immunotherapy in mice by reshaping the gut microbiome.

A team of researchers has identified a potential new strategy to prevent, or even reverse, immune checkpoint inhibitor–induced type 1 diabetes.

This article explores the relationship between the immune system and cancer and outlines therapeutic strategies that leverage a patient’s immune system to treat cancer.

A new study showed that high doses of steroids, when given before and/or during a specific type of immunotherapy, caused patients’ tumors to shrink less than those of patients not on steroids. Those patients also did not live as long.